MapLight Therapeutics, Inc.(MPLT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

MapLight Therapeutics, Inc. (MPLT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MPLT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), MapLight Therapeutics, Inc. reports net income of $-60.2M, free cash flow of $-44.9M. Top institutional holders of MPLT by reported 13-F value include Novo A/S, FCPM III SERVICES B.V., T. Rowe Price Investment Management, based on the most recent SEC filings. MPLT trades on the Nasdaq exchange and files with the SEC under CIK 1770069. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MPLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MapLight Therapeutics, Inc. directly from SEC EDGAR.